Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDAGlobeNewsWire • 05/29/26
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law FirmGlobeNewsWire • 05/18/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPLGlobeNewsWire • 05/12/26
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejectionReuters • 04/22/26
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock CrashesZacks Investment Research • 04/13/26
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewsWire • 04/10/26
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?Zacks Investment Research • 03/03/26
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should KnowZacks Investment Research • 02/12/26
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/03/26
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)GlobeNewsWire • 11/07/25
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/06/25
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced MelanomaGlobeNewsWire • 10/20/25